Literature DB >> 25278651

A comparative study of paediatric thermal burns treated with topical heparin and without heparin.

T S Venkatachalapathy1.   

Abstract

Following reports of heparin use in burn treatment, an ethics-committee-approved prospective randomized study with controls compared results obtained using traditional usual burn treatment without heparin with results in similar patients similarly treated with heparin added topically. The subjects were 100 consecutive burn patients (age <15 years) with second-degree superficial and deep burns of 5-45 % total body surface area size. Two largely similar cohort groups-a control group (C) and a heparin group (H) with 50 subjects per group-were randomly treated. The 50 control group patients received traditional routine treatment, including topical antimicrobial cream, debridement, and, when needed, skin grafts in the early postburn period. The 50 heparin group patients, without topical cream, were additionally treated, starting on day 1 postburn, with 200 IU/ml sodium aqueous heparin solution USP (heparin) dripped on the burn surfaces and inserted into the blisters two to four times a day for 1-2 days, and then only on burn surfaces for a total of 5-7 days, before skin grafting, when needed. Thereafter, control and heparin group treatment was similar. It was found that the heparin patients complained of less pain and received less pain medicine than the control patients. The heparin group needed fewer dressings and oral antibiotics than the control group. The 50 heparin group patients had 4 skin graftings (8 %), while the 50 control group patients had 10 (20 %). Five control group patients died (mortality 10 %). No heparin group patients died. The number of days in hospital for the heparin group versus control group was significantly less (overall P < 0.0001): 58 % of heparin group patients were discharged within 10 days versus 6 % of control group patients; 82 % of heparin group patients were out in 20 days versus 14 % of control group patients; 98 % of the heparin group versus 44 % of the control group were out in 30 days; and while 100 % of heparin group patients were discharged by day 40, 56 % of the control group required up to another 10 days. Burns in heparin group patients healed on average in 15 days (maximum period 37 days) versus an average of 25 days (maximum >48 days) in control group patients (P < 0.0006). Procedures and costs in the heparin group were much reduced compared with the control group. Differences between the heparin and control groups are presented for the sake of comparison. It was concluded that heparin applied topically for 5-7 days improved burn treatment: it reduced pain, pain medicine, dressings, and use of antibiotics; it significantly reduced IV fluids (P < 0.04), days in hospital (P < 0.0001), and healing time (P < 0.0006); and it reduced skin grafts, mortality, and costs.

Entities:  

Keywords:  IInd degree burns; Thermal burns; Topical heparin

Year:  2012        PMID: 25278651      PMCID: PMC4175678          DOI: 10.1007/s12262-012-0674-6

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  15 in total

Review 1.  The effects and uses of heparin in the care of burns that improves treatment and enhances the quality of life.

Authors:  M J Saliba
Journal:  Acta Chir Plast       Date:  1997

2.  Large burns in humans. Treatment with heparin.

Authors:  M J Saliba; W C Dempsey; J L Kruggel
Journal:  JAMA       Date:  1973-07-16       Impact factor: 56.272

3.  Trauma severity influences acute stress in young burned children.

Authors:  Jennifer E Drake; Frederick J Stoddard; J Michael Murphy; Heidi Ronfeldt; Nancy Snidman; Jerome Kagan; Glenn Saxe; Robert Sheridan
Journal:  J Burn Care Res       Date:  2006 Mar-Apr       Impact factor: 1.845

4.  Production of heparin-binding epidermal growth factor-like growth factor (HB-EGF) at sites of thermal injury in pediatric patients.

Authors:  D W McCarthy; M T Downing; D R Brigstock; M H Luquette; K D Brown; M S Abad; G E Besner
Journal:  J Invest Dermatol       Date:  1996-01       Impact factor: 8.551

5.  A comparative study of burns treated with topical heparin and without heparin.

Authors:  T S Venakatachalapathy; S Mohan Kumar; M J Saliba
Journal:  Ann Burns Fire Disasters       Date:  2007-12-31

6.  Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain.

Authors:  T Maciag; T Mehlman; R Friesel; A B Schreiber
Journal:  Science       Date:  1984-08-31       Impact factor: 47.728

Review 7.  Control of angiogenesis by heparin and other sulfated polysaccharides.

Authors:  J Folkman; Y Shing
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

8.  Studies on vascular smooth muscle cells and dermal fibroblasts in collagen matrices. Effects of heparin.

Authors:  H P Ehrlich; T R Griswold; J B Rajaratnam
Journal:  Exp Cell Res       Date:  1986-05       Impact factor: 3.905

9.  The effect of heparin on cell proliferation and type-I collagen synthesis by adult human dermal fibroblasts.

Authors:  A V Ferrao; R M Mason
Journal:  Biochim Biophys Acta       Date:  1993-01-22

10.  Mast cell heparin stimulates migration of capillary endothelial cells in vitro.

Authors:  R G Azizkhan; J C Azizkhan; B R Zetter; J Folkman
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Paediatric Partial-Thickness Burn Therapy: A Meta-Analysis and Systematic Review of Randomised Controlled Trials.

Authors:  Aba Lőrincz; Alex Váradi; Péter Hegyi; Zoltán Rumbus; Máté Tuba; Anna Gabriella Lamberti; Margit Varjú-Solymár; Andrea Párniczky; Bálint Erőss; András Garami; Gergő Józsa
Journal:  Life (Basel)       Date:  2022-04-21

2.  Systematic review of clinical outcome reporting in randomised controlled trials of burn care.

Authors:  Amber E Young; Anna Davies; Sophie Bland; Sara Brookes; Jane M Blazeby
Journal:  BMJ Open       Date:  2019-02-15       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.